Clinical trials: Stereotactic Body Radiation Therapy
Stage I Prostate Adenocarcinoma American Joint Committee on Cancer (AJCC) v7, Stage II Prostate Adenocarcinoma AJCC v7
Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
This phase I trial studies stereotactic body radiation therapy (SBRT) in treating patients with prostate cancer that is likely to come back or spread (high-risk) undergoing surgery.
- Conditions
- Stage I Prostate Adenocarcinoma American Joint Committee on Cancer (AJCC) v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
- Trial name
- NCT02830165
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Gastric Cancer, GastroEsophageal Cancer
Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers
This study is an open-label, phase II study with a safety lead-in to assess the response rate of induction olaparib and stereotactic beam radiotherapy (SBRT) followed by combination olaparib/pembrolizumab in patients with…
- Trial name
- NCT05379972
- Testing
- Pembrolizumab, Olaparib, Stereotactic Body Radiation Therapy
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- University of Colorado, Denver
Unresectable Melanoma, Metastatic Melanoma
A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma
This is a multicenter, open label, Phase 2 study, with 3 parallel cohorts. The aim of the study is to evaluate the efficacy of sotigalimab (APX005M) administered at 2 different schedules to adult participants with unresectable or…
- Conditions
- Unresectable Melanoma, Metastatic Melanoma, Cancer, Cancer of Skin
- Trial name
- NCT04337931
- Testing
- sotigalimab
- Where
- 19 sites in Poland, Spain
- Volunteers
- 45 people
- Sponsor
- Apexigen America, Inc.
Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.
The purpose of this study is to evaluate if the combination of nivolumab and a CCR2/CCR5 dual antagonist (BMS-813160) with GVAX is safe in patients with locally advanced pancreatic cancer (LAPC) who have received chemotherapy and…
- Trial name
- NCT03767582
- Testing
- Stereotactic Body Radiation (SBRT), Nivolumab, CCR2/CCR5 dual antagonist
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Colorectal Cancer, Colorectal Neoplasms
AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer
Background: T-cells are white blood cells that can find and kill germs and tumors. Cancer can keep T-cells from working. Researchers think a new drug called AMP-224 might help the T-cells in people with cancer.
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma
- Trial name
- NCT02298946
- Testing
- AMP-224, Stereotactic Body Radiation Therapy(SBRT), Cyclophosphamide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Chemoradiation +Gemcitabine +Continuous 5-FU (Fluorouracil) Followed by High Dose Brachytherapy/Stereotactic Radiation Boost in Locally Advanced Intra/Extrahepatic Cholangiocarcinoma
OBJECTIVES: This study proposes to evaluate the feasibility of delivery of this treatment in terms of toxicity. If toxicity is not acceptable, the treatment is not feasible.
- Trial name
- NCT00983541
- Testing
- Fluorouracil (5-FU), Brachytherapy or SBRT (Stereotactic body radiation therapy), Gemcitabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Utah
Renal Cell Carcinoma
Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours
This investigator driven study will examine the safety, efficacy and biological effects of combining pembrolizumab (MK-3475) an antibody targeted against anti-programmed cell death 1 (PD-1), with stereotactic ablative body…
- Trial name
- RAPPORT (NCT02855203)
- Testing
- Stereotactic Ablative Body Radiosurgery (SABR), Pembrolizumab
- Where
- 2 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Pancreatic Cancer
Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
This multi-institutional trial aims to evaluate the potential benefit and side effects of adding fractionated stereotactic body radiotherapy/surgery (SBRT) before and after chemotherapy with gemcitabine for locally advanced…
- Trial name
- NCT01146054
- Testing
- CyberKnife based stereotactic radiotherapy, Gemcitabine, Fludeoxyglucose (18F) (FDG)
- Where
- 3 sites in United States
- Volunteers
- 59 people
- Sponsor
- Stanford University
Thoracic Cancer, Abdominal Cancer
VisionRT-based Deep Inspiration Breath-hold (DIBH) Respiratory Motion Management Strategy, A Pilot Study for Thoracic and Abdominal Tumors
A more recent competing technology for implementing the DIBH technique is real-time surface photogrammetry using the AlignRT system (Vision RT Ltd., London, UK).
- Trial name
- NCT04686500
- Testing
- Tidal volume measured by spirometer and DIBH surface from CT image
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Texas Southwestern Medical Center
Pancreatic Cancer
Stereotactic Body Radiotherapy for Unresectable Pancreatic Cancer
This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of unresectable pancreatic cancer.
- Trial name
- NCT01346410
- Testing
- Stereotactic Body Radiotherapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Mercy Research